MK-1167
- Generic Name
- MK-1167
Neuphoria Advances Dual Clinical Programs with Merck Partnership Milestone and Phase 3 SAD Trial Progress
• Neuphoria Therapeutics has received a US$15M milestone payment from Merck following the initiation of a Phase 2 trial for MK-1167 in Alzheimer's disease, extending the company's cash runway to Q3 2026.
• The company's lead candidate BNC210 is progressing in a Phase 3 AFFIRM-1 trial for social anxiety disorder with topline results expected in Q3 2025, while a Phase 2b dose-ranging study for PTSD is planned for Q4 2025.
• BNC210 has demonstrated rapid-onset anti-anxiety effects across multiple anxiety disorders without sedation, cognitive impairment, or addiction potential, positioning it as a potential first-in-class therapeutic.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath